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Abstract: Clostridioides (also known as Clostridium) difficile is a Gram-positive anaerobic, spore pro-
ducing bacterial pathogen that causes severe gastrointestinal infection in humans. The current
chemotherapeutic options are inadequate, expensive, and limited, and thus inexpensive drug treat-
ments for C. difficile infection (CDI) with improved efficacy and specificity are urgently needed. To
improve the solubility of our cationic amphiphilic 1,1′-binaphthylpeptidomimetics developed earlier
that showed promise in an in vivo murine CDI model we have synthesized related compounds
with an N-arytriazole or N-naphthyltriazole moiety instead of the 1,1′-biphenyl or 1,1′-binaphthyl
moiety. This modification was made to increase the polarity and thus water solubility of the over-
all peptidomimetics, while maintaining the aromatic character. The dicationic N-naphthyltriazole
derivative 40 was identified as a C. difficile-selective antibacterial with MIC values of 8 µg/mL against
C. difficile strains ATCC 700057 and 132 (both ribotype 027). This compound displayed increased wa-
ter solubility and reduced hemolytic activity (32 µg/mL) in an in vitro hemolysis assay and reduced
cytotoxicity (CC50 32 µg/mL against HEK293 cells) relative to lead compound 2. Compound 40
exhibited mild efficacy (with 80% survival observed after 24 h compared to the DMSO control of
40%) in an in vivo murine model of C. difficile infection by reducing the severity and slowing the
onset of disease.
Keywords: antibacterial; Clostridioides (Clostridium) difficile; peptidomimetic; triazole
1. Introduction
Clostridioides (also known as Clostridium) difficile is a Gram-positive, anaerobic spore-
forming bacterium that causes mild to serious infections in the gastrointestinal tract (GIT)
due to the production of potent exotoxins (TcdA, TcdB, and CDT) that cause severe gas-
trointestinal damage [1–3]. The resilient endospores contaminate healthcare environments
and facilitate disease initiation, dissemination, and re-infection. In the GIT, spores require
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glycine and cholate derivatives for germination. In a healthy GIT, the microbiota metabo-
lizes cholate derivatives preventing germination of C. difficile spores. CDI occurs when the
normal GIT microbiota is disrupted or killed by conventional broad-spectrum antimicro-
bials [1]. Under these conditions the metabolism of cholate is significantly compromised,
facilitating the germination of spores into C. difficile vegetative cells [4,5].
CDI has a mortality rate of up to 8% [2] with the reoccurrence of infections occurring
in up to 20% of cases treated with vancomycin or metronidazole [6]. A 2019 Antibiotic
Resistance Threat Report from the US Centers for Disease Control and Prevention indicated
that in the USA in 2017 an estimated 223,900 cases of CDI in hospitalized patients resulted
in 12,800 deaths and $1 billion in attributed healthcare costs [7]. Thus, there is a significant
and important incentive to develop novel therapeutics that show selectivity for C. difficile
over other gut bacteria to effectively combat CDI. While fecal microbiota transplantation
can be effective for recurrent CDI, there can be adverse effects and the long-term impacts
are unknown [1,2,8].
Fidaxomicin was specifically approved by the FDA in 2011 for treating CDI [9]; result-
ing in approximately 50% less CDI recurrence compared to vancomycin [10] most likely
due to its greater selectivity for C. difficile, less impact on commensal enteric microflora
(i.e., Bacteroides spp.), and its ability to reduce C. difficile sporulation [11]. There are many
potential chemotherapeutics undergoing clinical trials for the treatment of CDI [12]. Other
small molecule chemotherapeutics currently under investigation for use against C. difficile,
include antimicrobial peptidomimetics [13–15], glycopeptides [16], bis-indoles [17], purine
derivatives [18], tetramic acids [19], nitroheterocycles [20], macrolides [21], and nylon-3
polymers [22]. Two vaccines are being investigated in clinical trials (Pfizer and Inter-
cell [23]), whereas bezlotoxumab (a monoclonal antibody targeting C. difficile TcdB) was
given FDA approval in 2016 as adjunctive therapy for patients undergoing antimicrobial
treatment who were at high risk of recurrent infection [24].
In our earlier work on the development of the cationic amphiphilic 1,1′-binaphthylpep-
tidomimetics, we established the pharmacophoric importance of a hydrophobic head group
(e.g., a binaphthyl moiety) connected to a dicationic peptide in the development of broad-
spectrum antibacterial agents. This led to the identification of compound 1 with potent
antibacterial activity against drug resistant Gram-positive bacteria with potential for topical
applications (Figure 1) [25]. More recent work in our laboratory has identified compounds
2–4 from a class of small molecule cationic amphiphilic 1,1′-biarylpeptidomimetics that
exert antibacterial activity through cytoplasmic membrane disruption [13,14]. These com-
pounds have IC50 values of 4–8 µg/mL against C. difficile (Figure 1). The efficacy of
these compounds at treating CDI in an in vivo murine CDI model was assessed against
vancomycin as a positive control with 10% DMSO as the negative control. Compound
2 appeared to protect the mice from disease at the 24 h point with a 50% survival rate
(2/4 mice) vs. 0% survival in the 10% DMSO group; this was not statistically significant
due to the small sample size. These results clearly showed that compound 2 exhibited a
notable positive effect in the treatment of CDI. Unfortunately compound 3 showed poor
solubility with precipitation during preparation in a 10% DMSO solution, and high in vitro
hemolytic activity against HEK293 cells. While compound 4 showed promising in vitro
properties, it performed poorly in the C. difficile murine model with a survival rate of
60% after 24 h, but a 0% rate after 48 h [13], despite its low hemolytic activity. Despite
some positive results, more water-soluble derivatives with lower hemolytic activity for
further in vivo murine CDI model studies needed to be developed. To achieve this aim,
we replaced the hydrophobic binaphthyl group found in 2 and 3 with an N-arytriazole
or N-naphthyltriazole moiety as shown in Figure 2. These modifications should retain
the aromatic character of these molecules while inducing a better polarity profile and
thereby increasing the water solubility of the overall peptidomimetics. It was not clear
at the start what effect these modifications would have on the antibacterial activities of
these newly proposed compounds or their specificity for C. difficile over other pathogenic
bacteria. Herein, we disclose the results of this investigation.
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(EDCI/HOBt) [26,27] to give amide 32 in 67% yield. This was followed by a standard cop-
per-catalyzed azide-alkyne cycloaddition reactions [28] with ethenylcyclohexane to give 
the corresponding 1,4-disubstituted 1,2,3-triazole product which was deprotected using 
TFA/CH2Cl2/H2O followed by treatment with ethereal HCl to yield the dicationic am-
phiphile 40 in 46% yield over two steps. The synthesis of the additional mono- and dica-
tionic peptidomimetic amphiphiles 10–16, 21–26, and 36–50 followed an analogous strat-
egy and is summarized in Schemes 1–3 with experimental and characterization details 
provided in the Supporting Information. 
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dicationic peptidomimetic amphiphiles 10–16, 21–26, and 36–50 followed an analogous
strategy and is summarized in Schemes 1–3 with experimental and characterization details
provided in the Supporting Information.
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The N-arytriazole and N-naphthyltriazole peptidomimetics were subjected to antimi-
crobial screening. In the first instance, minimum inhibitory concentrations (MICs) were
determined against a panel of Gram-positive (including two strains of C. difficile) and Gram-
negative pathogenic bacteria with vancomycin and the commercially available peptide
colistin as positive controls, respectively; the MICs are displayed in Table 1. The compounds
were then tested against a second panel of Gram-positive and Gram-negative pathogenic
bacteria and two fungi strains at the Community for Open Antimicrobial Drug Discovery
(CO-ADD)-these results are reported in the Supporting Information (Table S1) [29]. A
cytotoxicity concentration (CC50) assay was also performed by CO-ADD; the synthesized
compounds were tested at concentrations ≤32 µg/mL on human embryonic kidney cells
(HEK293 cells; ATCC CRL-1573) while hemolysis assays for lysis of human erythrocytes
were also performed. Vancomycin, colistin, fluconazole, and tamoxifen were used as
positive controls (see Table 1 for details). The CC50 and HC50 values are also sho n
in able 1.
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CC50 d HC50 e
1 10 32 64 32 32 32 16 128 >32 >32
2 11 32 64 32 32 32 16 128 >32 >32
3 12 32 64 32 32 32 16 128 >32 >32
4 13 32 64 32 32 32 16 128 >32 >32
5 14 128 128 32 32 32 32 >128 >32 >32
6 15 64 64 16 16 16 16 128 >32 >32
7 16 32 32 32 32 32 32 >128 >32 >32
8 21 128 >128 8 8 16 16 128 >32 >32
8 22 32 32 4 4 8 8 32 >32 >32
9 23 32 32 4 4 4 4 64 >32 >32
10 24 32 32 8 8 8 8 32 21.9 >32
11 25 32 64 4 4 8 8 16 >32 10.6
12 26 64 >128 8 8 16 4 64 23.5 >32
13 36 128 128 32 32 64 16 128 >32 >32
14 37 64 64 16 32 16 8 64 >32 >32
15 38 128 >128 128 128 >128 128 >128 32 32
16 39 64 32 32 64 32 16 128 >32 >32
17 40 8 8 16 16 32 16 64 32 32
18 41 16 16 8 8 8 16 128 16 32
19 42 8 8 8 8 8 8 32 32 32
20 43 128 128 16 16 64 4 64 >32 >32
21 44 32 32 8 4 16 4 64 >32 >32
22 45 128 128 16 16 64 4 128 >32 >32
23 46 128 128 32 32 64 16 128 >32 >32
24 47 128 128 32 32 64 16 128 >32 >32
25 48 >32 >32 >32 >32 >32 >32 >32 >32 24.5
26 49 >32 >32 32 >32 >32 >32 >32 >32 17.1
27 50 >32 >32 32 >32 >32 >32 >32 >32 19.8
vanc 0.5 0.5 1 1 4 1 >16 - -
colistin 0.25 0.25 0.25 0.125
tamoxifen 13.1
a Values are reported as MIC values in µg/mL. b C. difficile PCR Ribotype (RT027). c Methicillin resistant S. aureus (MRSA). d Cytotoxicity;
determined on HEK293 cells. e Hemolysis; HC50 values determined by lysis of human erythrocytes and % hemolysis was determined by
lysis of sheep erythrocytes. Vanc = vancomycin. Coloured cells refer to the same activities.
Preliminary screening revealed that compared to the previously synthesized com-
pounds 1–4, the new N-naphthyltriazole dicationic derivatives 40 and 42 showed the best
activities against the two C. difficile RT 027 strains, ATCC 700,057 and 132 with a similar
activity of 8 µg/mL compared to compounds 1, 3, and 4. However, they were generally
less active against the other Gram-positive and Gram-negative bacteria (Table 1). The
relative solubility ratios (relative to compound 1) [13] for 40 and 42 were 5 and 4 with
CLogP values of 4.46 and 4.39, respectively, when compared to 1 with a ClogP of 7.47.
Therefore, despite the better solubility profiles of these compounds, they failed to show
better activity against C. difficile. However, the increased solubility (enhanced polarity)
of derivatives 40–42 could be a factor in the reduced activities against the other bacteria,
when compared to compounds 1–4 (see Table 2). None of the other derivatives synthesized
in this study showed appreciable activity against C. difficile with MIC values ranging from
32 to 128 µg/mL (Table 1). Importantly, the remaining anti-bacterial results were generally
poor, however for these specific derivatives, these reduced activities could indicate reduced
capacity to interfere with normal GIT microbiota (Table 2). Compounds 40 and 42 showed
a slight reduction in cytotoxicity against HEK293 cells compared to compounds 2 and 4.
The hemolytic activity of these compounds was 32 µg/mL against human erythrocytes,
2-fold more than their IC50 values against C. difficile.
Antibiotics 2021, 10, 913 7 of 17
Table 2. Antimicrobial, cytotoxicity, and hemolytic activities of the three most active derivatives synthesized in this study a.
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Analysis of the anti-bacterial activities against other bacterial species indicated that
the monocationic naphthyltriazole derivatives 21–26 showed appreciable activity against
Staphylococcus aureus (including an MRSA strain) with MIC values between 4 and 8 µg/mL
(Table 1). Additionally, compound 21 had notable MIC values of 4 µg/mL against Ente-
rococcus faecalis and Streptococcus pneumoniae. An overview of activity shown in Table 1
showed “pockets” of activities focused on the naphthyl-based derivatives (21–26 and 40–45,
columns 1–4), with the monocationic examples (21–26) producing better outcomes against
the Gram positive strains. The second screening results (Table S1, Supporting Information)
were consistent with these results with analogous trends in activity against an additional
S. aureus strain.
The secondary testing (Table S1, Supporting Information) also identified compounds
21, 25, and 40–46 as having activity against the fungal strain Cryptococcus neoformans var.
grubii (ATCC208821) (MIC 4-8 µg/mL).
3. In Vivo Assay: Murine Model of CDI
Compound 40 was selected for further evaluation as an effective treatment for C. difficile
using a murine model of CDI study because of its sustained antimicrobial potency against
C. difficile and its better water solubility profile. The results from these studies are summa-
rized in Figure 3.
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to ice treated with DMSO (blue; Figure 3), although they still succumbed to infection
by day 2. Notably, at day 1 post-infection, mice treated with compound 40 sho ed 40
greater survival compared with mice treated with DMSO (Figure 3a), although there
was no effect on mouse weight (Figure 3b), or spore numbers shed in the feces of these
animals (Figure 3c), suggesting that compound 40 was not impacting C. difficile colonization.
Furthermore, on day 1 post-infection, treatment with compound 40 resulted in a lower
overall cage appearance score when compared to DMSO (Figure 3d), which suggested that
this compound was delaying diarrheal onset although there was no significant difference
in individual fecal score (Figure 3e) or physiological appearance score (Figure 3f) detected
between the two groups of mice (Figure 3e). Thus, collectively these data suggest that
compound 40 may reduce the severity of disease caused by C. difficile.
4. Materials and Methods
Synthetic methods and general characterization and analysis were as described previ-
ously [13].
Notes and other considerations. Known reagents that were not available commer-
cially were prepared as reported using known methods and is detailed in the Supporting
Information, [14,32–35].
4.1. General Synthesis Procedures
4.1.1. General Procedure I: Alkylation of Phenols (with Ethyl Bromoacetate)
A solution of the phenol (1 eq) in dry DMF (5 mL/mmol substrate) was stirred during
the addition of K2CO3 (3 eq). Ethyl bromoacetate (1.3 eq) was added at room temperature
and stirring was continued at rt for 12 h, before being diluted with EtOAc (2 × 50 mL). The
resulting mixture was washed with water (2 × 50 mL), brine (2 × 50 mL), dried (MgSO4),
filtered, and concentrated under vacuum. The residue was subjected to silica gel flash
column chromatography to afford the desired ester product.
4.1.2. General Procedure II: ster Hydrolysis
l
f s l ti (5 L/mmol) at rt. The mixture wa stirred at rt for
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2 h, then acidified with 1 M HCl (25 mL). The resulting mixture was extracted with EtOAc
(2 × 25 mL) and the combined extracts washed with brine (50 mL), dried (MgSO4), filtered,
and concentrated under vacuum to afford the acid product.
4.1.3. General Procedure III: Amide Coupling
A mixture of the amine (1.0 eq), carboxylic acid (1.0 eq), EDC.HCl (1.2 eq), HOBt (1.1 eq),
and TEA (1 eq) in dichloromethane/acetonitrile solution (10 mL/mmol amine) was stirred
at rt for the specified time. The mixture was concentrated (if >5.0 mL dichloromethane/
acetonitrile), and then the resulting residue dissolved in EtOAc (25 mL for reactions that
contained ≤1.0 mmol amine or 25 mL/mmol amine for larger scale reactions) and washed
with aqueous HCl (1.0 M–2 × 25 mL), saturated aqueous NaHCO3 (3 × 25 mL), and
brine (1 × 25 mL). The organic solution was dried (MgSO4), filtered, concentrated and
subjected to further purification via flash chromatography (if required) to furnish the
targeted amide product.
4.1.4. General Procedure IV: Copper-Catalyzed Azide-Alkyne Cycloaddition
To a stirred solution of the azide (1.0 eq) and alkyne (2.0–3.0 eq) in tert-butanol/water
(4:1) at rt was added CuSO4·5H2O (0.2 eq), followed by sodium ascorbate (0.4 eq). The
reaction was stirred at rt (unless noted otherwise) for the specified time. To the mixture
was added aqueous saturated NH4Cl solution (1 mL), and water (20 mL) with the mix-
ture then extracted with EtOAc (20 mL for reactions that contained ≤1.0 mmol azide or
20 mL/mmol azide for larger scale reactions). The organic layers were back-washed with
water (2 × 25 mL), brine (2 × 25 mL), then dried (MgSO4), filtered, concentrated under
vacuum and subjected to flash chromatography to afford the desired 1,4-disubstituted
1,2,3-triazole product.
4.1.5. General Procedure VII: Amine Deprotection (N-Boc and/or N-Pbf Removal)
To a solution of the N-protected amine (1.0 eq) in CH2Cl2 (30 mL/mmol substrate)
(if the substrate contained an N-Pbf moiety, H2O (20.0 eq) was added to the solution) was
added TFA (30.0 mL/mmol substrate) and then stirred at rt overnight (>16 h). The solvent
was removed and the resulting residue dissolved in CH2Cl2 (30 mL/mmol substrate).
Excess anhydrous HCl (2.0 M in Et2O, 15 mL/mmol substrate, 30.0 eq) was added and the
solvent was then removed. The residue was then dissolved in a minimal volume of CH2Cl2
(or MeOH) and excess Et2O (25 mL for ≤0.1 mmol substrate) was added, resulting in a
precipitate of the hydrochloride salt of the amine. The reaction mixture was filtered; the
resulting filtrate collected, concentrated, triturated with Et2O (3 × 20 mL); and the solids
then dissolved in MeOH. The solution was concentrated and dried in vacuo to yield the
mono or di-hydrochloride salt as a thin, translucent film that usually required scratching
with a spatula, producing a fine hygroscopic powder or amorphous gum.
4.2. Representative Synthesis of Compound 40
4.2.1. Ethyl 2-((1-iodonaphthalen-2-yl)oxy)acetate
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Following General Procedure I, 1-iodonaphthol (1.00 g, 3.70 mmol), K2CO3 (1.53 g,
11.11 mmol), and ethyl bromoacetate (0.80 g, 4.81 mmol) were stirred in DMF (8 mL) at
rt for 16 h to give the titled ester (0.68 g, 52%) as a pale yellow waxy solid after flash
chromat graphy ov r silica g l (EtOAc/n-hexane-10:90). TLC (EtOAc/n-hexane-20:80):
Rf = 0.6; 1H NMR (400 MHz, CDCl3) δ 8.16 (d, J = 7.2 Hz, 1H, H8), 7.78 (d, J = 7.2 Hz,
1H, H5), 7.72 (d, J = 8.0 Hz, 1H, H4), 7.54 (t, J = 7.2 Hz, 1H, H7), 7.39 (t, J = 7.2 Hz, 1H,
H6), 7.08 (d, J = 8.0 Hz, 1H, H3), 4.80 (s, 2H, H1′), 4.27 (q, J = 5.6 Hz, 2H, OCH2CH3),
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1.29 (t, J = 5.6 Hz, 3H, OCH2CH3); 13C NMR (101 MHz, CDCl3) δ 168.7 (C = O), 155.6 (C2),
135.8 (C8a), 131.7 (C4a), 130.6 (C4), 130.5 (C8), 128.4 (C7), 128.3 (C5), 121.1 (C6), 114.4 (C3),
89.47 (C1), 67.6 (C1′), 61.7 (OCH2CH3) 14.3 (OCH2CH3); IR (neat) νmax 2981, 1756, 1622,
1593, 1502, 1462, 1349, 1291, 1200, 1151, 1134, 1096, 1028, 801, 764, 747 cm−1; MS (ESI +ve)
m/z 379 ([M + Na]+, 100%); HRMS (ESI + ve TOF) calcd for C14H13O3NaI 378.9807, found
378.9801 ([M + Na]+).
4.2.2. Ethyl 2-((1-(4-isopentyl-1H-1,2,3-triazol-1-yl)naphthalen-2-yl)oxy)acetate
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atmosphere. The reaction mixture was stirred and heated at 75 °C for 16 h. The reaction 
was cooled to rt and aqueous saturated NH4Cl solution (3 mL) was added, and the mix-
ture was extracted with EtOAc (2 × 25 mL). The combined extracts were washed with 
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2-((1-(4-Isopentyl-1H-1,2,3-triazol-1-yl)naphthalen-2-yl)oxy)acetic acid (17) 
 
Following General Procedure II, ethyl 2-((1-(4-isopentyl-1H-1,2,3-triazol-1-yl)naph-
thalen-2-yl)oxy)acetate (0.07 g, 0.19 mmol) and 7% KOH solution (0.5 mL) were stirred in 
ethanol (2 mL) at rt for 2 h to give after acidification the acid 17 (0.04 g, 62%) as a white 
solid. M.P: 152–154 °C. TLC (EtOAc/n-hexane-100:0): Rf = 0.2; 1H NMR (500 MHz, CDCl3) 
δ 8.00 (d, J = 9.0 Hz, 1H, H8′), 7.88 (d, J = 7.5 Hz, 1H, H5′), 7.69 (s, 1H, H5), 7.54–7.46 (m, 
2H, H6′/H7′), 7.47–7.29 (m, 2H, H3′/H4′), 4.78 (s, 2H, H1′′′), 2.91–2.87 (m, 2H, H1′′), 1.71–
1.68 (m, 3H, H2′′/H3′′), 0.98 (d, J = 6.0 Hz, 6H, H4′′/H5′′), COOH resonance was not ob-
served; 13C NMR (126 MHz, CDCl3) δ 170.6 (C = O), 150.4 (C2′), 148.4 (C8a′), 132.2 (C4), 
130.7 (C4a′), 129.6 (C4′), 128.8 (C5′), 128.2 (C7′), 125.6 (C8′), 124.9 (C6′), 121.7 (C5), 120.9 
(C3′), 114.4 (C1′), 66.8 (C1′′′), 38.5 (C2′′), 28.0 (C1′′), 23.7 (C3′′), 22.6 (C4′′/C5′′; Observed by 
gHMBC); IR (neat) ?̅?max 3147, 2954, 2929, 2868, 1731, 1631, 1600, 1514, 1483, 1429, 1366, 
1284, 1213, 1151, 1118, 1087, 1062, 923, 806, 748 cm−1; MS (ESI +ve) m/z 362 ([M + Na]+, 40%), 
340 ([M + H]+, 100%); HRMS (ESI + ve TOF) calcd for C19H22N3O3 340.1661, found 340.1667 
([M + H]+). 
To a stirred solution of ethyl 2-(2-iodophenoxy)acetate (0.20 g, 0.54 mmol), 5-methyl-
1-hexyne (0.16 g, 1.64 mmol), CuI (0.02 g, 0.11 mmol), NaN3 (0.04 g, 0.60 mmol), and
sodium ascorbate (0.04 g, 0.22 mmol) in DMSO (2.5 mL) in H2O (0.5 mL) was added
racemic trans-N,N′-dimethyl cyclohexane-1,2-diamine (0.016 g, 0. 1 ol) at rt under
a nitrogen atmosphere. The reaction mixture was stirred and heated at 75 ◦C for 16 h.
The reaction was cooled to rt and aqueous saturated NH4Cl solution (3 mL) was added,
and the mixture was extracted with EtOAc (2 × 25 mL). The combined extracts were
washed with water (25 mL), brine (25 mL) and dried (MgSO4). The solution was filtered,
concentrated under vacuum and the residue was subjected to silica gel flash column
chromatography (EtOAc/n-hexane-10:90→ 100:0) to afford the titled compound (0.05 g,
25%) as a yellow waxy solid. TLC (EtOAc/n-hexane-33:67); Rf = 0.4; 1H NMR (400 MHz,
CDCl3) δ 7.97 (d, J = 7.2 Hz, 1H, H8′), 7.84 (d, J = 6.4 Hz, 1H, H5′), 7.67 (s, 1H, H5), 7.49–7.41
(m, 2H, H6′/H7′), 7.27–7.25 (m, 2H, H3′/H4′), 4.67 (s, 2H, H1′ ′ ′), 4.22 (q, J = 5.6 Hz, 2H,
OCH2CH3), 2.89 (t, J = 5.6 Hz, 2H, H1′ ′), 1.73–1.67 (m, 3H, H2′ ′/H3′ ′), 1.26 (t, J = 5.6 Hz,
3H, OCH2OCH3), 0.99 (d, J = 4.0 Hz, 6H, H4′ ′/H5′ ′); 13C NMR (101 MHz, CDCl3) δ 168.5
(C = O), 150.5 (C2′), 148.1 (C8a′), 131.6 (C4), 131.3 (C4a′), 129.5 (C4′), 128.5 (C5′), 127.9 (C7′),
125.3 (C8′), 124.7 (C6′), 122.1 (C5), 121.3 (C3′), 114.3 (C1′), 66.7 (C1′ ′ ′), 61.6 (OCH2CH3),
38.6 (C2′ ′), 27.9 (C1′ ′), 23.8 (C3′ ′), 22.5 (C4′ ′/C5′ ′; Observed by gHMBC), 14.2 (OCH2CH3);
IR (neat) νmax 2954, 2928, 2868, 1748, 1632, 1600, 1513, 1483, 1454, 1430, 1366, 1288, 1206,
1150, 1117, 1087, 1042, 806, 749 cm−1; MS (ESI +ve) m/z 390 ([M +Na]+, 100%); HRMS (ESI
+ve TOF) calcd for C21H26N3O3 368.1974, found 368.1985 ([M + H]+).
4.2.3. 2-((1-(4-Isopentyl-1H-1,2,3-triazol-1-yl)naphthalen-2-yl)oxy)acetic acid (17)
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waxy solid. TLC (EtOAc/n-hexane-33:67); Rf = 0. ; 1H NMR (400 MHz, CDCl3) δ 7.97 (d, J 
= 7.2 Hz, 1H, H8′), 7.84 (d, J = 6.4 Hz, 1H, H5′), 7.67 (s, 1H, H5), 7.49–7.41 (m, 2H, H6′/H7′), 
7.27–7.25 (m, 2H, H3′/H4′), 4.67 (s, 2H, H1′′′), 4.22 (q, J = 5.6 Hz, 2H, OCH2CH3), 2.89 (t, J = 
5.6 Hz, 2 , H1′′), 1.73–1.67 (m, 3H, H2′′/H3′′), 1.26 (t, J = 5.6 Hz, 3H, OCH2OCH3), 0.99 (d, 
J = 4.0 Hz, 6H, H4′′/H5′′); 13C NMR (101 MHz, CDCl3) δ 168.5 (C = O), 150.5 (C2′), 148.1 
(C8a′), 131.6 (C4), 131.3 (C4a′), 129.5 (C4′), 128.5 (C5′), 127.9 (C7′), 125.3 (C8′), 124.7 (C6′), 
122.1 (C5), 121.3 (C3′), 114.3 (C1′), 66.7 (C1′′′), 61.6 (OCH2CH3), 38.6 (C2′′), 27.9 (C1′′), 23.8 
(C3′′), 22.5 (C4′′/C5′′; Observed by gHMBC), 14.2 (OCH2CH3); IR (neat) ?̅?max 2954, 2928, 
2868, 1748, 1632, 1600, 1513, 1483, 1454, 1430, 1366, 1288, 1206, 1150, 1117, 1087, 1042, 806, 
749 cm−1; MS (ESI +ve) m/z 390 ([M +Na]+, 100%); HRMS (ESI +ve TOF) calcd for C21H26N3O3 
368.1974, found 368.1985 ([M + H]+). 
2-((1-(4-Isopentyl-1H-1,2,3-triazol-1-yl)naphthalen-2-yl)oxy)acetic acid (17) 
 
Following General Procedure II, ethyl 2-((1-(4-isopentyl-1H-1,2,3-triazol-1-yl)naph-
thalen-2-yl)oxy)acetate (0.07 g, 0.19 mmol) and 7% KOH solution (0.5 mL) were stirred in 
ethanol (2 mL) at rt for 2 h to give after acidification the acid 17 (0.04 g, 62%) as a white 
solid. M.P: 152–154 °C. TLC (EtOAc/n-hexane-100:0): Rf = 0.2; 1H NMR (500 MHz, CDCl3) 
δ 8.00 (d, J = 9.0 Hz, 1H, H8′), 7.88 (d, J = 7.5 Hz, 1H, H5′), 7.69 (s, 1H, H5), 7.54–7.46 (m, 
2H, H6′/H7′), 7.47–7.29 (m, 2H, H3′/H4′), 4.78 (s, 2H, H1′′′), 2.91–2.87 (m, 2H, H1′′), 1.71–
1.68 (m, 3H, H2′′/H3′′), 0.98 (d, J = 6.0 Hz, 6H, H4′′/H5′′), COOH resonance was not ob-
served; 13C NMR (126 MHz, CDCl3) δ 170.6 (C = O), 150.4 (C2′), 148.4 (C8a′), 132.2 (C4), 
130.7 (C4a′), 129.6 (C4′), 128.8 (C5′), 128.2 (C7′), 125.6 (C8′), 124.9 (C6′), 121.7 (C5), 120.9 
(C3′), 114.4 (C1′), 66.8 (C1′′′), 38.5 (C2′′), 28.0 (C1′′), 23.7 (C3′′), 22.6 (C4′′/C5′′; Observed by 
gHMBC); IR (neat) ?̅?max 3147, 2954, 2929, 2868, 1731, 1631, 1600, 1514, 1483, 1429, 1366, 
1284, 1213, 1151, 1118, 1087, 1062, 923, 806, 748 cm−1; MS (ESI +ve) m/z 362 ([M + Na]+, 40%), 
340 ([M + H]+, 100%); HRMS (ESI + ve TOF) calcd for C19H22N3O3 340.1661, found 340.1667 
([M + H]+). 
Following General Procedure II, ethyl 2-((1-(4-isopentyl-1H-1,2,3-triazol-1-yl)naphth-
alen-2-yl)oxy)acetate (0.07 g, 0.19 mmol) and 7% KOH solution (0.5 mL) were stirred in
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ethanol (2 mL) at rt for 2 h to give after acidification the acid 17 (0.04 g, 62%) as a white
solid. M.P: 152–154 ◦C. TLC (EtOAc/n-hexane-100:0): Rf = 0.2; 1H NMR (500 MHz, CDCl3)
δ 8.00 (d, J = 9.0 Hz, 1H, H8′), 7.88 (d, J = 7.5 Hz, 1H, H5′), 7.69 (s, 1H, H5), 7.54–7.46
(m, 2H, H6′/H7′), 7.47–7.29 (m, 2H, H3′/H4′), 4.78 (s, 2H, H1′ ′ ′), 2.91–2.87 (m, 2H, H1′ ′),
1.71–1.68 (m, 3H, H2′ ′/H3′ ′), 0.98 (d, J = 6.0 Hz, 6H, H4′ ′/H5′ ′), COOH resonance was not
observed; 13C NMR (126 MHz, CDCl3) δ 170.6 (C = O), 150.4 (C2′), 148.4 (C8a′), 132.2 (C4),
130.7 (C4a′), 129.6 (C4′), 128.8 (C5′), 128.2 (C7′), 125.6 (C8′), 124.9 (C6′), 121.7 (C5), 120.9
(C3′), 114.4 (C1′), 66.8 (C1′ ′ ′), 38.5 (C2′ ′), 28.0 (C1′ ′), 23.7 (C3′ ′), 22.6 (C4′ ′/C5′ ′; Observed
by gHMBC); IR (neat) νmax 3147, 2954, 2929, 2868, 1731, 1631, 1600, 1514, 1483, 1429, 1366,
1284, 1213, 1151, 1118, 1087, 1062, 923, 806, 748 cm−1; MS (ESI +ve) m/z 362 ([M + Na]+,
40%), 340 ([M + H]+, 100%); HRMS (ESI + ve TOF) calcd for C19H22N3O3 340.1661, found











To a reaction vessel charged with azide 7 [30] (1.38 g, 3.16 mmol), Fmoc-L-Lys(Boc)-
OH (1.62 g, 3.50 mmol), EDCI (0.67 g, 3.50 mmol) and HOBt (0.53 g, 3.50 mmol) was added 
CH2Cl2 (10 mL) and the mixture was stirred at rt for 12 h. The reaction mixture was con-
centrated and diluted with water (100 mL) and extracted with EtOAc (3 × 100 mL). The 
organic extracts were combined and washed with HCl (1 M–100 mL), aqueous NaHCO3 
(100 mL), brine (25 mL), dried (MgSO4) and concentrated to give a pale-yellow residue. 
This residue was purified via flash chromatography over SiO2 (MeOH/CH2Cl2 = 4:96) to 
afford the titled compound as an off-white foam (1.50 g, 54%). TLC (MeOH/CH2Cl2–10:90) 
Rf = 0.52; 1H-NMR (400 MHz, CDCl3) δ 7.77–7.70 (m, 2H, H4′′/H5′′), 7.55 (d, J = 7.5 Hz, 2H, 
H1′′/H8′′), 7.55 (brs, 1H, βCONH), 7.41–7.32 (m, 2H, H2′′/H7′′), 7.29–7.21 (m, 2H, H3′′/H6′′), 
7.17 (brs, 1H, αCONH), 6.31–6.24 (m, 2H, NH2 (guanidine)), 6.19–6.09 (brs, 1H, N5-H), 
4.82–4.72 (brs, 1H, LysN1-H), 4.33 (d, J = 7.4 Hz, 2H, H10′′), 4.25–4.07 (m, 2H, Lys5/H9′′), 
4.07–3.97 (m, 1H, H2), 3.41–3.23 (m, 2H, H1), 3.23–2.98 (m, 4H, H5/Lys1), 2.89 (s, 2H, H3′), 
2.55 (s, 3H, C6′-CH3), 2.48 (s, 3H, C4′-CH3), 2.06 (s, 3H, C7′-CH3), 1.67 (s, 6H, C2′-CH3), 
1.55–1.35 (m, 19H, H3/H4/Lys2/Lys3/Lys4/C(CH3)3); 13C NMR (101 MHz, CDCl3) δ 172.7 
(Cβ), 158.8 (C7a′), 156.7 (Cα), 156.4 (C = N), 156.2 (COOC(CH3)3), 143.85 (C1a′′or C8a′′), 
143.83 (C8a′′ or C1a′′), 143.82 (C4a′′ or C5a′′), 143.6 (C5a′′ or C4a′′), 138.3 (C3a′), 132.8 (C6′), 
132.2 (C4′), 127.8 (C3′′/C6′′), 127.1 (C4′′/C5′′), 125.0 (C2′′/C7′′), 124.7 (C5′), 120.0 (C1′′/C8′′), 
117.6 (C7′), 86.4 (C2′), 79.3 (C(CH3)3), 67.3 (C10′′), 55.1 (Lys5), 54.8 (C1), 48.8 (C2), 47.0 
(C9′′), 43.2 (C3′), 40.9 (C5), 39.9 (Lys1), 31.9 (Lys2), 29.5 (Lys4), 29.3 (C3), 28.6 (C2′-(CH3)2), 
28.4 (C(CH3)3), 25.5 (C4), 22.5 (Lys3), 19.3 (C6′-CH3), 17.9 (C4′-CH3), 12.5 C7′-CH3); IR (neat) ?̅?max 3322, 2101, 1634, 1548, 1450, 1248, 1165, 1092, 739, 567 cm−1; MS (ESI +ve) m/z 888 ([M 
+ H]+), 910 ([M + Na]+); HRMS (ESI +ve TOF) calcd for C45H61N9O8SNa 910.4262, found 




To a reaction vessel charged with azide 7 [30] (1.38 g, 3.16 mmol), Fmoc-L-Lys(Boc)-OH
(1.62 g, 3.50 mmol), EDCI (0.67 g, 3.50 mmol) and HOBt (0.53 g, 3.50 mmol) was added
CH2Cl2 (10 mL) and the mixture was stirred at rt for 12 h. The reaction mixture was
concentrated and diluted with water (100 mL) and extracted with EtOAc (3 × 100 mL). The
organic extracts were combined and washed with HCl (1 M–100 mL), aqueous NaHCO3
(100 mL), brine (25 mL), ried (MgSO4) and concentrated to give a p le-yellow esidue.
This residue was purified via flash chromatography over SiO2 (MeOH/CH2Cl2 = 4:96) to
afford the titled compound as an off-white foam (1.50 g, 54%). TLC (MeOH/CH2Cl2–10:90)
Rf = 0.52; 1H-NMR (400 MHz, CDCl3) δ 7.77–7.70 (m, 2H, H4′ ′/H5′ ′), 7.55 (d, J = 7.5 Hz,
2H, H1′ ′/H8′ ′), 7.55 (brs, 1H, βCONH), 7.41–7.32 (m, 2H, H2′ ′/H7′ ′), 7.29–7.21 (m, 2H,
H3′ ′/H6′ ′), 7.17 (brs, 1H, αCONH), 6.31–6.24 (m, 2H, NH2 (guanidine)), 6.19–6.09 (brs,
1H, N5-H), 4.82–4.72 (brs, 1H, LysN1-H), 4.33 (d, J = 7.4 Hz, 2H, H10′ ′), 4.25–4.07 (m, 2H,
Lys5/H9′ ′), 4.07–3.97 (m, 1H, H2), 3.41–3.23 (m, 2H, H1), 3.23–2.98 (m, 4H, H5/Lys1),
2.89 (s, 2H, H3′), 2.55 (s, 3H, C6′-CH3), 2.48 (s, 3H, C4′-CH3), 2.06 (s, 3H, C7′-CH3), 1.67
(s, 6H, C2′-CH3), 1.55–1.35 (m, 19H, H3/H4/Lys2/Lys3/Lys4/C(CH3)3); 13C NMR (101
MHz, CDCl3) δ 172.7 (Cβ), 158.8 (C7a′), 156.7 (Cα), 156.4 (C = N), 156.2 (COOC(CH3)3),
143.85 (C1a′ ′or C8a′ ′), 143.83 (C8a′ ′ or C1a′ ′), 143.82 (C4a′ ′ or C5a′ ′), 143.6 (C5a′ ′ or C4a′ ′),
138.3 (C3a′), 132.8 (C6′), 132.2 (C4′), 127.8 (C3′ ′/C6′ ′), 127.1 (C4′ ′/C5′ ′), 125.0 (C2′ ′/C7′ ′),
124.7 (C5′), 120.0 (C1′ ′/C8′ ′), 117.6 (C7′), 86.4 (C2′), 79.3 (C(CH3)3), 67.3 (C10′ ′), 55.1 (Lys5),
54.8 (C1), 48.8 (C2), 47.0 (C9′ ′), 43.2 (C3′), 40.9 (C5), 39.9 (Lys1), 3 .9 (Lys2), 29.5 (Lys4),
29.3 (C3), 28.6 (C2′-(CH3)2), 28.4 (C(CH3)3), 25.5 (C4), 22.5 (Lys3), 19.3 (C6′-CH3), 17.9
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(C4′-CH3), 12.5 C7′-CH3); IR (neat) νmax 3322, 2101, 1634, 1548, 1450, 1248, 1165, 1092, 739,
567 cm−1; MS (ESI +ve) m/z 888 ([M + H]+), 910 ([M + Na]+); HRMS (ESI +ve TOF) calcd
for C45H61N9O8SNa 910.4262, found 910.4218 ([M + Na]+).
4.2.5. Tert-butyl ((R)-5-amino-6-(((R)-1-azido-5-(2-((2,2-dimethyl-2,3-dihydrobenzofuran-
5-yl)sulfonyl)guanidino)pentan-2-yl)amino)-6-oxohexyl)carbamate (31)






To a reaction vessel charged with azide 7 [30] (1.38 g, 3.16 mmol), Fmoc-L-Lys(Boc)-
OH (1.62 g, 3.50 mmol), EDCI (0.67 g, 3.50 mmol) and HOBt (0.53 g, 3.50 mmol) was added 
CH2Cl2 (10 mL) and the mixture was stirred at rt for 12 h. The reaction mixture was con-
centrated and diluted with water (100 mL) and extracted with EtOAc (3 × 100 mL). The 
organic extracts were combined and washed with HCl (1 M–100 mL), aqueous NaHCO3 
(100 mL), brine (25 mL), dried (MgSO4) and concentrated to give a pale-yellow residue. 
This residue was purified via flash chromatography over SiO2 (MeOH/CH2Cl2 = 4:96) to 
afford the titled compound as an off-white foam (1.50 g, 54%). TLC (MeOH/CH2Cl2–10:90) 
Rf = 0.52; 1H-NMR (400 MHz, CDCl3) δ 7.77–7.70 (m, 2H, H4′′/H5′′), 7.55 (d, J = 7.5 Hz, 2H, 
H1′′/H8′′), 7.55 (brs, 1H, βCONH), 7.41–7.32 (m, 2H, H2′′/H7′′), 7.29–7.21 (m, 2H, H3′′/H6′′), 
7.17 (brs, 1H, αCONH), 6.31–6.24 (m, 2H, NH2 (guanidine)), 6.19–6.09 (brs, 1H, N5-H), 
4.82–4.72 (brs, 1H, LysN1-H), 4.33 (d, J = 7.4 Hz, 2H, H10′′), 4.25–4.07 (m, 2H, Lys5/H9′′), 
4.07–3.97 (m, 1H, H2), 3.41–3.23 (m, 2H, H1), 3.23–2.98 (m, 4H, H5/Lys1), 2.89 (s, 2H, H3′), 
2.55 (s, 3H, C6′-CH3), 2.48 (s, 3H, C4′-CH3), 2.06 (s, 3H, C7′-CH3), 1.67 (s, 6H, C2′-CH3), 
1.55–1.35 (m, 19H, H3/H4/Lys2/Lys3/Lys4/C(CH3)3); 13C NMR (101 MHz, CDCl3) δ 172.7 
(Cβ), 158.8 (C7a′), 156.7 (Cα), 156.4 (C = N), 156.2 (COOC(CH3)3), 143.85 (C1a′′or C8a′′), 
143.83 (C8a′′ or C1a′′), 143.82 (C4a′′ or C5a′′), 143.6 (C5a′′ or C4a′′), 138.3 (C3a′), 132.8 (C6′), 
132.2 (C4′), 127.8 (C3′′/C6′′), 127.1 (C4′′/C5′′), 125.0 (C2′′/C7′′), 124.7 (C5′), 120.0 (C1′′/C8′′), 
117.6 (C7′), 86.4 (C2′), 79.3 (C(CH3)3), 67.3 (C10′′), 55.1 (Lys5), 54.8 (C1), 48.8 (C2), 47.0 
(C9′′), 43.2 (C3′), 40.9 (C5), 39.9 (Lys1), 31.9 (Lys2), 29.5 (Lys4), 29.3 (C3), 28.6 (C2′-(CH3)2), 
28.4 (C(CH3)3), 25.5 (C4), 22.5 (Lys3), 19.3 (C6′-CH3), 17.9 (C4′-CH3), 12.5 C7′-CH3); IR (neat) ?̅?max 3322, 2101, 1634, 1548, 1450, 1248, 1165, 1092, 739, 567 cm−1; MS (ESI +ve) m/z 888 ([M 
+ H]+), 910 ([M + Na]+); HRMS (ESI +ve TOF) calcd for C45H61N9O8SNa 910.4262, found 
910.4 18 ([M + Na]+). 
Tert-butyl ((R)-5-amino-6-(((R)-1-azido-5-(2-((2,2-dimethyl-2,3-dihydrobenzofu-
ran-5- l)sulfonyl)guanidino)p ntan-2-yl)ami o)-6-oxohexyl)carbamate (31). 
 
To a solution of the above Fmoc-protected amine (1.50 g, 1.69 mmol) in acetonitrile
(15 mL) was added piperidine (0.25 mL, 1.5 eq.) and the reaction was stirred vigorously at
rt for 12 h. The reaction mixture was diluted with MeOH (50 mL) and extracted with hexane
(50 mL) multiple times until TLC analysis showed no byproduct (dibenzofulvene piperidine
adduct) present in the MeOH layer. The MeOH extract was concentrated under reduced
pressure to give 31 as an off-white foam (0.80 g, 71%). TLC (MeOH/CH2Cl2–10:90) Rf = 0.2;
1H-NMR (500 MHz, CDCl3) δ 7.61 (brs, 1H, N2-H), 6.42–6.20 (m, 3H, N5-H/NH2 (guani-
dine)), 4.82–4.72 (m, 1H, LysN1-H), 4.12–3.99 (m, 1H, Lys5), 3.46–3.29 (m, 3H, H1/H2), 3.29–
3.14 (m, 2H, H5), 3.14–3.04 (m, 2H, Lys1), 2.96 (s, 2H, C3′), 2.58 (s, 3H, C6′-CH3), 2.52 (s, 3H,
C4′-CH3), 2.10 (s, 3H, C7′-CH3), 1.62–1.31 (m, 25H, H3/H4/Lys2/Lys3/Lys4/C(CH3)3/C2′-
(CH3)2), N5H2 resonance was not observed; 13C-NMR (126 MHz, CDCl3) δ 158.8 (C7a′),
156.6 (C = O), 156.4 (C = N), 138.5 (C3a′), 133.2 (C4′), 132.4 (C6′), 124.7 (C5′), 117.6 (C7′), 86.5
(C2′), 79.4 ((C(CH3)3), 55.1 (Lys5), 55.0 (C1), 46.9 (C2), 43.4 (C3′), 40.9 (C5), 40.4 (Lys1), 34.7
(Lys4), 30.1 (Lys2), 29.8 (C3), 28.8 (C2′-(CH3)2), 28.6 (C(CH3)3), 25.8 (C4), 22.7 (Lys3), 19.4
(C6′-CH3), 18.1 (C4′-CH3), 12.6 (C7′-CH3), COO(C(CH3)3) resonance was not observed; IR
(neat) νmax 3327, 2101, 1685, 1620, 1551, 1454, 1366, 1278, 1250, 1168, 1094, 665, 569 cm−1;
MS (ESI +ve) m/z 666 ([M + H]+); HRMS (ESI +ve TOF) calcd for C30H52N9O6S 666.3761,
found 666.3741 ([M + H]+).




Antibiotics 2021, 10, × FOR PEER REVIEW 12 of 16 
 
To a solution of the above Fmoc-protected amine (1.50 g, 1.69 mmol) in acetonitrile 
(15 mL) was added piperidine (0.25 mL, 1.5 eq.) and the reaction was stirred vigorously 
at rt for 12 h. The reaction mixture was diluted with MeOH (50 mL) and extracted with 
hexane (50 mL) multiple times until TLC analysis showed no byproduct (dibenzofulvene 
piperidine adduct) present in the MeOH layer. The MeOH extract was concentrated under 
reduced pressure to give 31 as an off-white foam (0.80 g, 71%). TLC (MeOH/CH2Cl2–10:90) 
Rf = 0.2; 1H-NMR (500 MHz, CDCl3) δ 7.61 (brs, 1H, N2-H), 6.42–6.20 (m, 3H, N5-H/NH2 
(guanidine)), 4.82–4.72 (m, 1H, LysN1-H), 4.12–3.99 (m, 1H, Lys5), 3.46–3.29 (m, 3H, 
H1/H2), 3.29–3.14 (m, 2H, H5), 3.14–3.04 (m, 2H, Lys1), 2.96 (s, 2H, C3′), 2.58 (s, 3H, C6′-
CH3), 2.52 (s, 3H, C4′-CH3), 2.10 (s, 3H, C7′-CH3), 1.62–1.31 (m, 25H, 
H3/H4/Lys2/Lys3/Lys4/C(CH3)3/C2′-(CH3)2), N5H2 resonance was not observed; 13C-NMR 
(126 MHz, CDCl3) δ 158.8 (C7a′), 156.6 (C = O), 156.4 (C = N), 138.5 (C3a′), 133.2 (C4′), 132.4 
(C6′), 124.7 (C5′), 117.6 (C7′), 86.5 (C2′), 79.4 ((C(CH3)3), 55.1 (Lys5), 55.0 (C1), 46.9 (C2), 
43.4 (C3′), 40.9 (C5), 40.4 (Lys1), 34.7 (Lys4), 30.1 (Lys2), 29.8 (C3), 28.8 (C2′-(CH3)2), 28.6 
(C(CH3)3), 25.8 (C4), 22.7 (Lys3), 19.4 (C6′-CH3), 18.1 (C4′-CH3), 12.6 (C7′-CH3), 
COO(C(CH3)3) resonance was not observed; IR (neat) ?̅?max 3327, 2101, 1685, 1620, 1551, 
1454, 1366, 1278, 1250, 1168, 1094, 665, 569 cm−1; MS (ESI +ve) m/z 666 ([M + H]+); HRMS 
(ESI +ve TOF) calcd for C30H52N9O6S 666.3761, found 666.3741 ([M + H]+). 
Tert-butyl ((R)-6-(((R)-1-azido-5-(2-((2,2,4,6,7-pentamethyl-2,3-dihydrobenzofu-
ran-5-yl)sulfonyl)guani ino)pentan-2-yl)amino)-5-(2-((1-(4-isopentyl-1H-1,2,3-triazol-
1-yl) ap thalen-2-yl)oxy acetamido)-6-oxohexyl)carbamate (32) 
 
Following General Procedure III, 2-((1-(4-isopentyl-1H-1,2,3-triazol-1-yl)naphtha-
len-2-yl)oxy)acetic acid 17 (0.12 g, 0.35 mmol), tert-butyl ((R)-5-amino-6-(((R)-1-azido-5-(2-
((2,2-dimethyl-2,3-dihydrobenzofuran-5-yl)sulfonyl)guanidino)pentan-2-yl)amino)-6-
oxohexyl) carbamate 57 (0.24 g, 0.35 mmol), EDCI.HCl (0.08 g, 0.39 mmol), HOBt (0.06 g, 
0.39 mmol), and TEA (0.03 g, 0.35 mmol) were stirred in CH2Cl2 (5 mL) at rt for 12 h to 
give the acetamide 65 (0.22 g, 64%) as an off-white solid. M.P: 236–238 °C. TLC 
(MeOH/CH2Cl2-10:90): Rf = 0.5; 1H NMR (400 MHz, CDCl3) δ 8.05 (d, J = 8.5 Hz, 1H, Ar8), 
7.89 (d, J = 8.5 Hz, 1H, Ar5), 7.65 (s, 1H, H5), 7.54–7.47 (m, 2H, Ar4/βCONH), 7.37 (d, J = 
8.5 Hz, 1H, Ar7), 7.26–7.19 (m, 2H, Ar6/Ar3), 6.85 (brs, 1H, αCONH), 6.36–6.08 (m, 3H, 
N5′-H/NH2 (guanidine)), 5.00 (brs, 1H, LysN1-H), 4.69 (ABq, J = 16.5 Hz, 2H, OCHAHB), 
4.42–4.36 (m, 1H, Lys5), 4.02–3.96 (m, 1H, H2′), 3.44–2.94 (m, 6H, H1′/H5′/Lys1), 2.88 (s, 
2H, H3′′), 2.88–2.84 (m, 2H, H1′′′), 2.55 (s, 3H, C4′′-CH3), 2.48 (s, 3H, C6′′-CH3), 2.06 (s, 3H, 
C7′′-CH3), 2.00–1.86 (m, 4H, H4′/Lys4), 1.84–1.60 (m, 7H, H3′/Lys3/H2′′′/H3′′′), 1.44 (s, 6H, 
C2′′(CH3)2), 1.39 (s, 9H, C(CH3)3), 1.32–1.22 (m, 2H, Lys2), 0.9 (d, J = 5.0 Hz, 6H, H4′′′/H5′′′); 
13C NMR (101 MHz, CDCl3) δ 171.9 (βC = O), 168.1 (αC = O), 158.7 (C7a′′), 156.4 (C = N), 
150.1 (Ar2), 149.1 (COOC(CH3)3), 138.4 (Ar8a), 133.4 (C4), 132.6 (C4′′), 132.46 (C6′′), 132.44 
(C3a′′), 130.6 (C5′′), 129.4 (Ar4), 129.1 (Ar4a), 128.48 (C7′′), 128.47 (Ar5), 125.7 (Ar7), 124.7 
(Ar8), 121.1 (C5), 120.3 (Ar6), 117.5 (Ar3), 113.8 (Ar1), 86.5 (C2′′), 79.2 (C(CH3)3), 68.0 
(OCHAHB), 54.8 (Lys5), 53.6 (C1′), 43.4 (C2′), 40.8 (C2′′′), 40.2 (C5′), 38.6 (C3′′), 38.5 (Lys1), 
31.79 (Lys4), 31.74 (C3′), 29.4 (Lys2), 28.7 (C2′′-(CH3)2), 28.6 ((CH3)3), 28.0 (C1′′′), 25.5 (C4′), 
23.8 (C3′′′), 22.8 (C4′′′/C5′′′), 22.6 (Lys3), 19.4 (C4′′-CH3), 18.1 (C6′′-CH3), 12.6 (C7′′-CH3); IR 
(neat) ?̅?max 3405, 3317, 3415, 3057, 2953, 2868, 2100, 1664, 1631, 1600, 1546, 1514, 1484, 1452, 
Following General Procedure III, 2-((1-(4-isopentyl-1H-1,2,3-triazol-1-yl)naphthalen-
2-yl)oxy)acetic acid 17 (0.12 g, 0.35 mmol), tert-butyl ((R)-5-amino-6-(((R)-1-azido-5-(2-((2,2-
dimethyl-2,3-dihydrobenzofuran-5-yl)sulfonyl)guanidino)pentan-2-yl)amino)-6-oxohexyl)
carbamate 57 (0.24 g, 0.35 mmol), EDCI.HCl (0.08 g, 0.39 mmol), HOBt (0.06 g, 0.39 mmol),
and TEA (0.03 g, 0.35 mmol) were stirred in CH2Cl2 (5 mL) at rt for 12 h to give the
acetamide 65 (0.22 g, 64%) as an off-white solid. M.P: 236–238 ◦C. TLC (MeOH/CH2Cl2-
10:90): Rf = 0.5; 1H NMR (400 MHz, CDCl3) δ 8.05 (d, J = 8.5 Hz, 1H, Ar8), 7.89 (d, J = 8.5 Hz,
1H, Ar5), 7.65 (s, 1H, H5), 7.54–7.47 (m, 2H, Ar4/βCONH), 7.37 (d, J = 8.5 Hz, 1H, Ar7),
7.26–7.19 (m, 2H, Ar6/Ar3), 6.85 (brs, 1H, αCONH), 6.36–6.08 (m, 3H, N5
′
-H/NH2 (guani-
dine)), 5.00 (brs, 1H, LysN1-H), 4.69 (ABq, J = 16.5 Hz, 2H, OCHA B), 4.42–4.36 (m, 1H,
Lys5), 4.02–3.96 (m, 1H, H2′), 3.44–2.94 (m, 6H, H1′/H5′/Lys1), 2.88 (s, 2H, H3′ ′), 2.88–2.84
(m, 2H, H1′ ′ ′), 2.55 (s, 3H, C4′ ′-CH3), 2.48 (s, 3H, C6′ ′-CH3), 2.06 (s, 3H, C7′ ′-CH3), 2.00–1.86
(m, 4H, H4′/Lys4), 1.84–1.60 (m, 7H, H3′/Lys3/H2′ ′ ′/H3′ ′ ′), 1.44 (s, 6H, C2′ ′(CH3)2), 1.39
(s, 9H, C(CH3)3), 1.32–1.22 (m, 2H, Lys2), 0.9 (d, J = 5.0 Hz, 6H, H4′ ′ ′/H5′ ′ ′); 13C NMR (101
MHz, CDCl3) δ 171.9 (βC = O), 168.1 (αC = O), 158.7 (C7a′ ′), 156.4 (C = N), 150.1 (Ar2),
149.1 (COOC(CH3)3), 138.4 (Ar8a), 133.4 (C4), 132.6 (C4′ ′), 13 .46 (C6′ ′), 132.44 (C3a′ ′),
130.6 (C5′ ′), 129.4 (Ar4), 129.1 (Ar4a), 128.48 (C7′ ′), 128.47 (Ar5), 125.7 (Ar7), 124.7 (Ar8),
121.1 (C5), 120.3 (Ar6), 117.5 (Ar3), 113.8 (Ar1), 86.5 (C2′ ′), 79.2 (C(CH3)3), 68.0 (OCHAHB),
54.8 (Lys5), 53.6 (C1′), 43.4 (C2′), 40.8 (C2′ ′ ′), 40.2 (C5′), 38.6 (C3′ ′), 38.5 (Lys1), 31.79 (Lys4),
31.74 (C3′), 29.4 (Lys2), 28.7 (C2′ ′-(CH3)2), 28.6 ((CH3)3), 28.0 (C1′ ′ ′), 25.5 (C4′), 23.8 (C3′ ′ ′),
22.8 (C4′ ′ ′/C5′ ′ ′), 22.6 (Lys3), 19.4 (C4′ ′-CH3), 18.1 (C6′ ′-CH3), 12.6 (C7′ ′-CH3); IR (neat)
νmax 3405, 3317, 3415, 3057, 2953, 2868, 2100, 664, 1631, 1600, 1546, 1514, 1484, 1452, 1406,
1390, 1366, 1265, 1247, 1165, 1106, 1090, 1044, 994, 970, 852, 781, 733, 661, 641 cm−1; MS (ESI
+ve) m/z 987 ([M + H]+, 100%); HRMS (ESI +ve TOF) calcd for C49H71N12O8S 987.5239,
found 987.5272 ([M + H]+).
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1406, 1390, 1366, 1265, 1247, 1165, 1106, 1090, 1044, 994, 970, 852, 781, 733, 661, 641 cm−1; 
MS (ESI +ve) m/z 987 ([M + H]+, 100%); HRMS (ESI +ve TOF) calcd for C49H71N12O8S 
987.5239, found 987.5272 ([M + H]+). 
(R)-6-Amino-N-((R)-1-(4-cyclohexyl-1H-1,2,3-triazol-1-yl)-5-guanidinopentan-2-
yl)-2-(2-((1-(4-isopentyl-1H-1,2,3-triazol- -yl)n phthalen-2-yl)oxy)acetamido)hexana-
mide dihyd ochloride (40) 
 
Following General Procedure IV, azide 32 (0.08 g, 0.08mmol), cyclohexylacetylene 
(0.03 g, 0.24 mmol), CuSO4∙5H2O (0.004 g, 0.01 mmol) and sodium ascorbate (0.006 g, 0.03 
mmol) were stirred in t-BuOH (2.0 mL) and H2O (0.5 mL) for 16 h to give the triazole 
product as an off-white gum after flash chromatography over SiO2 gel (MeOH/CH2Cl2–
0:100 → 8:92). Following General Procedure VII, the intermediate (0.06 g, 0.05 mmol) was 
dissolved in CH2Cl2 (2 mL), treated with H2O (0.02 g, 1.00 mmol) and CF3COOH (1 mL) 
followed by work-up with ethereal HCl (3 mL) to give the amine salt 40 (0.03 g, 46% over 
two steps) as an off-white solid that rapidly transitioned to a sticky gum. [𝛼]  + 59.1 (c 
0.0052, MeOH); 1H NMR (400 MHz, CD3OD) δ 8.30 (s, 1H, H5), 8.29 (s, 1H, Hγ), 8.18 (d, J 
= 9.2 Hz, 1H, Ar8), 7.98 (d, J = 7.5 Hz, 1H, Ar5), 7.61 (ddd, J = 9.2, 9.2, 1.7 Hz, 1H, Ar7), 
7.57–7.49 (m, 2H, Ar6/Ar4), 7.14 (d, J = 8.3 Hz, 1H, Ar3), 4.93–4.89 (m, 2H, OCHAHB), 4.77–
4.72 (m, 1H, H1′), 4.59–4.53 (m, 1H, H1′), 4.37–4.32 (m, 1H, Lys5), 4.12–4.09 (m, 1H, H2′), 
3.18–3.14 (m, 2H, H5′), 2.95–2.91 (m, 2H, Lys1), 2.84–2.78 (m, 3H, H1′′′/H1′′), 2.00–1.96 (m, 
2H, Lys4), 1.74–1.60 (m, 14H, H2′′′/H3′′′/Lys2/H3′/H4′/H2′′/H3′′/H4′′/H5′′/H6′′), 1.48–1.21 
(m, 7H, Lys3/H2′′/H3′′/H4′′/H5′′/H6′′), 1.01 (d, J = 6.2 Hz, 6H, H4′′′/H5′′′); 13C NMR (101 
MHz, CD3OD) δ 173.0 (βC = O), 169.1 (αC = O), 157.1 (C = N), 150.8 (Ar2), 148.7 (C4), 147.6 
(Cδ), 132.5 (Ar8a), 130.3 (Ar4), 129.1 (Ar4a), 128.6 (Ar5), 128.0 (Ar7), 126.9 (Ar8), 125.5 (C5), 
125.1 (Cγ), 120.2 (Ar6), 119.1 (Ar3), 113.9 (Ar1), 67.4 (OCHAHB), 55.7 (C1′), 53.5 (Lys5), 49.3 
(C2′), 40.4 (C5′), 39.0 (Lys1), 37.9 (C2′′′), 33.4 (C1′′), 31.6 (C2′′), 31.5 (C6′′), 30.9 (Lys4), 28.1 
(Lys2), 27.5 (C1′′′), 26.5 (C3′), 25.2 (C4′′), 25.0 (C3′′/C5′′), 24.8 (C3′′′), 22.6 (C4′), 22.5 
(C4′′′/C5′′′), 21.3 (Lys3); IR (neat) ?̅?max 3348, 3265, 3202, 3066, 2932, 2860, 1662, 1544, 1514, 
1483, 1451, 1384, 1366, 1349, 1279, 1220, 1168, 1117, 1081, 1049, 816, 749, 668, 585 cm−1; MS 
(ESI + ve) m/z 743 ([M–2HCl + H]+, 60%), 372 ([M–2HCl + H]2+, 100%); HRMS (ESI + ve 
TOF) calcd for C39H59N12O3 743.4833, found 743.4866 ([M–2HCl + H]+). 
4.3. Microbiological Assays 
Primary screening (Gram-positive bacteria). Primary MIC assays were performed 
as described by the Clinical and Laboratory Standards Institute for aerobic [36] and an-
aerobic [37] bacteria. MIC values for vancomycin were within acceptable QC ranges [38]. 
Secondary screening (MRSA and Gram-negative bacteria) and cytotoxicity assay–
performed by the Community for Open Antimicrobial Drug Discovery (CO-ADD). 
Samples were provided to CO-ADD [29] for antimicrobial screening by whole cell growth 
inhibition assays. 
Bacterial Inhibition–MIC Assay. These were performed as described previously 
[13,29]. 
Cytotoxicity Assay. These were performed as described previously [13,29]. 
Haemolysis assay (sheep erythrocytes). These were performed as described previ-
ously [13]. 
Following General Procedure IV, azide 32 (0.08 g, 0.08mmol), cyclohexylacetylene
(0.03 g, 0.24 mmol), CuSO4·5H2O (0.004 g, 0.01 mmol) and sodium ascorbate (0.006 g,
0.03 mmol) were stirred in t-BuOH (2.0 mL) and H2O (0.5 mL) for 16 h to give the triazole
product as an off-white gum after flash chromatography over SiO2 gel (MeOH/CH2Cl2–
0:100→ 8:92). Following General Procedure VII, the intermediate (0.06 g, 0.05 mmol) was
dissolved in CH2Cl2 (2 mL), treated with H2O (0.02 g, 1.00 mmol) and CF3COOH (1 mL)
followed by work-up with ethereal HCl (3 mL) to give the amine salt 40 (0.03 g, 46% over
two steps) as an off-white solid that rapidly transitioned to a sticky gum. [α]23D + 59.1 (c
0.0052, MeOH); 1H NMR (400 MHz, CD3OD) δ 8.30 (s, 1H, H5), 8.29 (s, 1H, Hγ), 8.18 (d,
J = 9.2 Hz, 1H, Ar8), 7.98 (d, J = 7.5 Hz, 1H, Ar5), 7.61 (ddd, J = 9.2, 9.2, 1.7 Hz, 1H, Ar7),
7.57–7.49 (m, 2H, Ar6/Ar4), 7.14 (d, J = 8.3 Hz, 1H, Ar3), 4.93–4.89 (m, 2H, OCHAHB), 4.77–
4.72 (m, 1H, H1′), 4.59–4.53 (m, 1H, H1′), 4.37–4.32 (m, 1H, Lys5), 4.12–4.09 (m, 1H, H2′),
3.18–3.14 (m, 2H, H5′), 2.95–2.91 (m, 2H, Lys1), 2.84–2.78 (m, 3H, H1′ ′ ′/H1′ ′), 2.00–1.96
(m, 2H, Lys4), 1.74–1.60 (m, 14H, H2′ ′ ′/H3′ ′ ′/Lys2/H3′/H4′/H2′ ′/H3′ ′/H4′ ′/H5′ ′/H6′ ′),
1.48–1.21 (m, 7H, Lys3/H2′ ′/H3′ ′/H4′ ′/H5′ ′/H6′ ′), 1.01 (d, J = 6.2 Hz, 6H, H4′ ′ ′/H5′ ′ ′);
13C NMR (101 MHz, CD3OD) δ 173.0 (βC = O), 169.1 (αC = O), 157.1 (C = N), 150.8 (Ar2),
148 7 (C4), 147.6 (Cδ), 132.5 ( r8a), 130.3 (Ar4), 129.1 (Ar4a), 128.6 (Ar5), 128.0 (Ar7), 126.9
(Ar8), 125.5 (C5), 125.1 (Cγ), 120.2 (Ar6), 119.1 (Ar3), 113.9 (Ar1), 67.4 (OCHAHB), 55.7
(C1′), 53.5 (Lys5), 49.3 (C2′), 40.4 (C5′), 39.0 (Lys1), 37.9 (C2′ ′ ′), 33.4 (C1′ ′), 31.6 (C2′ ′), 31.5
(C6′ ′), 30.9 (Lys4), 28.1 (Lys2), 27.5 (C1′ ′ ′), 26.5 (C3′), 25.2 (C4′ ′), 25.0 (C3′ ′/C5′ ′), 24.8 (C3′ ′ ′),
22.6 (C4′), 22.5 (C4′ ′ ′/C5′ ′ ′), 21.3 (Lys3); IR (neat) νmax 3348, 3265, 3202, 3066, 2932, 2860,
1662, 1544, 1514, 1483, 1451, 1384, 1366, 1349, 1279, 1220, 1168, 1117, 1081, 1049, 816, 749,
668, 585 cm−1; MS (ESI + ve) m/z 743 ([M–2HCl + H]+, 60%), 372 ([M–2HCl + H]2+, 100%);
HRMS (ESI + ve TOF) calcd for C39H59N12O3 743.4833, found 743.4866 ([M–2HCl + H]+).
4.3. Microbiological Assays
Primary screening (Gram-positive bacteria). Primary MIC assays were performed
as described by the Clinical and Laboratory Standards Institute for aerobic [36] and anaero-
bic [37] bacteria. MIC values for vancomycin were within acceptable QC ranges [38].
Secondary screening MRSA and Gram-negative bacteria) and cytotoxicity assay–
performed by the Community for Open Antimicrobial Drug Discovery (CO-ADD). Samples
were provided to CO-ADD [29] for antimicrobial screening by whole cell growth inhibition
assays.
Bacterial Inhibition–MIC Assay. These were performed as described previously [13,29].
Cytotoxicity Assay. These were performed as described previously [13,29].
Haemolysis assay (sheep erythrocytes). These were performed as described previ-
ously [13].
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Hemolysis assay (human erythrocytes)–HC50 determination. These were performed
as described previously [13,29].
4.4. In Vivo Murine Model of CDI Treatment
Disease Treatment Model. These experiments were performed as previously de-
scribed [39–42]. Mice were humanely killed at the onset of severe disease or at the end of
the experiment (day 4), as previously described [43].
Statistical Analysis. Statistical analysis was performed using Prism 7 (GraphPad
Software). The Kaplan–Meier survival curves were assessed using a log-rank (Mantel–Cox)
test. Weight loss, spore shedding, fecal consistency, and physiological appearance data
were analyzed by one-way ANOVA with a post hoc Tukey’s multiple comparison test.
Differences in data values were considered significant at a p value of <0.05.
5. Conclusions
This study reported the next generation of hydrophobic anchored cationic pep-
tidomimetics as antibacterial agents, with a focus on targeting CDI. A major aim was
to improve the solubility profile of these compounds to allow for sufficient solubility for
efficient administration of the drug while maintaining gut availability and antibacterial ac-
tivity. The naphthyltriazole derivates containing either a monocationic or dicationic amino
acid side chain were generally the most effective, with compounds 40 and 42, possessing
terminal cyclohexyl and benzyl moieties, respectively, exhibiting MIC values of 8 µg/mL.
Naphthyltriazole 40 was selected for an in vivo murine model trials of CDI but ex-
hibited only mild evidence of in vivo efficacy indicating that further investigation into the
structural and biological parameters affecting the in vivo efficacy of these antibacterial
peptidomimetics is required, as the observed in vitro efficacy did not translate directly
into in vivo efficacy. We have already reported that a correlation exists between increased
hemolytic activity and an increase in hydrophobic/cationic ratio [15]; unfortunately, com-
pound 40 exhibited a slight increase in hemolytic activity relative to the majority of tested
compounds in this class with an HC50 value of 32 µg/mL. While the selectivity ratio could
be more substantial, this is acceptable for the future development of these gastrointestinal
focused compounds. We have previously reported a comparative solubility assay for this
class of antimicrobial agents with increasing numerical values corresponding to better
aqueous solubility relative to compound 1 (which possesses a value of 1) [13]. Compound
40 showed a better solubility ratio with an assay value of 5, relative to our lead compound
2 with a value 3—this is also reflected in the CLogP values of 4.46 and 5.76 for 41 vs. 2,
respectively. These outcomes were confirmed with no issues during the mouse model trials
with sufficient solubility in the dosage regimen. Variations on the triazole and O-naphthyl
substituents could be made in future studies with the view of enhancing antibacterial
activity against C. difficile.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/antibiotics10080913/s1, Figures S1–S85: Details of synthesis and characterization data for
compounds; Table S1: Secondary antimicrobial screening a–(bacteria and fungi), Murine model
studies experimental procedures.
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